Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Epitheliopathy
Status:
Not yet recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101
versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The
study will be conducted in up to 15 centers in the United States (US).